N‐glycan engineering of a plant‐produced anti‐CD20‐hIL‐2 immunocytokine significantly enhances its effector functions
Sign Up to like & getrecommendations! Published in 2018 at "Biotechnology and Bioengineering"
DOI: 10.1002/bit.26503
Abstract: Anti‐CD20 recombinant antibodies are among the most promising therapeutics for the treatment of B‐cell malignancies such as non‐Hodgkin lymphomas. We recently demonstrated that an immunocytokine (2B8‐Fc‐hIL2), obtained by fusing an anti‐CD20 scFv‐Fc antibody derived from… read more here.
Keywords: plant; effector functions; glycosylation; anti cd20 ... See more keywords
ROLE OF CHLORAMBUCIL IN COMBINATION OR NOT WITH ANTI‐CD20 AS FRONTLINE THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA IN "REAL LIFE"
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.49_2631
Abstract: CLL/SLL pts. Most surprisingly is the high rate of infusion related reactions; however, these were mainly confined to grade 2 reactions and grade 3 reactions were much lower than in the CLL11 trial (Goede V,… read more here.
Keywords: therapy; anti cd20; cd20 frontline; combination anti ... See more keywords
Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
Sign Up to like & getrecommendations! Published in 2017 at "Small"
DOI: 10.1002/smll.201602267
Abstract: Antibody-drug conjugate (ADC) targeting antigens expressed on the surface of tumor cells are an effective approach for delivering drugs into the cells via antigen-mediated endocytosis. One of the well-known tumor antigens, the CD20 of B-lymphocyte,… read more here.
Keywords: sortase generated; lineage lymphomas; ofa vcmmae; anti cd20 ... See more keywords
Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice
Sign Up to like & getrecommendations! Published in 2019 at "Diabetologia"
DOI: 10.1007/s00125-019-04974-y
Abstract: Autoreactive B cells escape immune tolerance and contribute to the pathogenesis of type 1 diabetes. While global B cell depletion is a successful therapy for autoimmune disease, the fate of autoreactive cells during this treatment… read more here.
Keywords: anti insulin; insulin cells; cd20 treatment; anti cd20 ... See more keywords
Anti-CD20 therapy ameliorates β cell function and rebalances Th17/Treg cells in NOD mice
Sign Up to like & getrecommendations! Published in 2022 at "Endocrine"
DOI: 10.1007/s12020-021-02965-x
Abstract: Anti-CD20 therapy delays type 1 diabetes mellitus (T1DM) progression in both nonobese diabetic (NOD) mice and new-onset patients. The mechanism is not completely defined. This study aimed to investigate the effects of anti-CD20 therapy on… read more here.
Keywords: nod mice; anti cd20; cell function; th17 treg ... See more keywords
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2021 at "CNS Drugs"
DOI: 10.1007/s40263-021-00843-8
Abstract: Anti-CD20 therapies have demonstrated considerable efficacy in the treatment of relapsing multiple sclerosis, constituting a high-efficacy treatment approach for reducing relapse risk and mitigating disability progression. These therapies have been shown to strongly deplete circulating… read more here.
Keywords: pharmacological attributes; multiple sclerosis; cd20 therapies; anti cd20 ... See more keywords
Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.108112
Abstract: More than 100 monoclonal antibodies (mAbs) have been approved by FDA. The mechanism of action (MoA) involves in neutralization of a specific target via the Fab region and Fc effector functions through Fc region, while… read more here.
Keywords: antibody; adcp; cellular phagocytosis; antibody dependent ... See more keywords
Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study.
Sign Up to like & getrecommendations! Published in 2021 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2021.102981
Abstract: BACKGROUND Anti-CD20 monoclonal antibodies (mAb) have demonstrated their drastic efficacy in the treatment of active relapsing-remitting multiple sclerosis (RR-MS). This study investigates the management of their initiation after another disease modifying therapy (DMT). The objective… read more here.
Keywords: monoclonal antibodies; switching towards; cd20 monoclonal; study ... See more keywords
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
Sign Up to like & getrecommendations! Published in 2021 at "Multiple Sclerosis and Related Disorders"
DOI: 10.1016/j.msard.2021.103251
Abstract: Background : The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20 monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of SARS-CoV-2 immunoglobulin G (IgG) are believed to have a predictive value for… read more here.
Keywords: sars cov; multiple sclerosis; vaccine; anti cd20 ... See more keywords
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study
Sign Up to like & getrecommendations! Published in 2022 at "Multiple Sclerosis and Related Disorders"
DOI: 10.1016/j.msard.2022.103560
Abstract: Background Antibody responses to SARS-CoV-2 vaccination are impaired in people with multiple sclerosis (MS) under anti-CD20 therapies. It is however unclear, whether patients who received the basic immunization prior to anti-B cell medication start respond… read more here.
Keywords: vaccine cohort; cd20 vaccine; antibody; anti cd20 ... See more keywords
PKPD assessment of the anti-CD20 antibody obinutuzumab in cynomolgus monkey is feasible despite marked anti-drug antibody response in this species.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2019.07.013
Abstract: The pharmacokinetics (PK) of the anti-CD20 monoclonal antibody obinutuzumab was assessed following single intravenous dosing to cynomolgus monkeys. In addition, the pharmacokinetic-pharmacodynamic (PKPD) relationship for B-cell depletion was characterized. The PKPD model was used to… read more here.
Keywords: response; antibody; antibody obinutuzumab; clearance ... See more keywords